Clinical Trial Update: Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial investigating the combination of Vitamin C with a Tyrosine Kinase Inhibitor in non-small cell lung cancer patients with EGFR mutation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tyrosine Kinase Inhibitor
• Vitamin C (ascorbic acid)

Snippet

Sponsor: Clifford Hospital, Guangzhou, China | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: UNKNOWN